X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5726) 5726
Book Review (765) 765
Publication (500) 500
Newsletter (58) 58
Book Chapter (18) 18
Book / eBook (7) 7
Dissertation (4) 4
Magazine Article (4) 4
Conference Proceeding (3) 3
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5246) 5246
humans (3985) 3985
male (2500) 2500
animals (2271) 2271
pharmacology & pharmacy (1968) 1968
sulfonamides - pharmacokinetics (1918) 1918
sulfonamides - pharmacology (1815) 1815
female (1736) 1736
sulfonamides - therapeutic use (1407) 1407
sulfonamides - administration & dosage (1337) 1337
adult (1195) 1195
middle aged (1128) 1128
pharmacokinetics (1046) 1046
rats (929) 929
sulfonamides (902) 902
sulfonamides - adverse effects (898) 898
sulfonamides - chemistry (800) 800
aged (739) 739
mice (663) 663
chemistry, medicinal (661) 661
dose-response relationship, drug (634) 634
analysis (563) 563
treatment outcome (559) 559
sulfonamides - blood (558) 558
administration, oral (557) 557
oncology (545) 545
drug interactions (502) 502
celecoxib (493) 493
structure-activity relationship (473) 473
cancer (472) 472
drug therapy, combination (420) 420
research (391) 391
drug therapy (376) 376
pharmacology/toxicology (363) 363
rats, sprague-dawley (359) 359
sulfonamides - metabolism (359) 359
care and treatment (356) 356
medicine & public health (353) 353
biochemistry & molecular biology (352) 352
pharmacology (349) 349
chemistry, organic (344) 344
therapy (342) 342
rosuvastatin calcium (341) 341
area under curve (340) 340
cell line, tumor (334) 334
abridged index medicus (332) 332
sulfonamides - chemical synthesis (323) 323
dogs (314) 314
safety (303) 303
in-vitro (299) 299
young adult (298) 298
efficacy (297) 297
expression (295) 295
pyrimidines - pharmacokinetics (292) 292
biological availability (285) 285
adolescent (284) 284
pyrimidines - therapeutic use (284) 284
drugs (283) 283
double-blind method (282) 282
kinetics (279) 279
hiv infections - drug therapy (275) 275
time factors (272) 272
molecular structure (263) 263
metabolism (259) 259
dosage and administration (256) 256
toxicology (254) 254
article (251) 251
chemistry, analytical (250) 250
health aspects (249) 249
drug administration schedule (247) 247
half-life (243) 243
antineoplastic agents - pharmacology (241) 241
aged, 80 and over (234) 234
apoptosis (234) 234
pyrimidines - administration & dosage (224) 224
inhibitors (222) 222
cross-over studies (218) 218
darunavir (214) 214
internal medicine (211) 211
antineoplastic agents - therapeutic use (207) 207
clinical trials as topic (207) 207
clinical trials (206) 206
drug design (203) 203
sulfonamide (203) 203
inhibition (201) 201
pyrimidines - pharmacology (201) 201
rats, wistar (201) 201
ritonavir (195) 195
double-blind (193) 193
tissue distribution (192) 192
infectious diseases (190) 190
pharmacodynamics (189) 189
proteins (189) 189
reproducibility of results (188) 188
rosuvastatin (187) 187
protein binding (184) 184
pyrimidines - adverse effects (184) 184
chromatography, high pressure liquid (182) 182
models, molecular (182) 182
protease inhibitors (181) 181
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5705) 5705
German (39) 39
Japanese (14) 14
Russian (14) 14
French (13) 13
Italian (7) 7
Spanish (7) 7
Chinese (4) 4
Polish (3) 3
Czech (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Korean (1) 1
Portuguese (1) 1
Romanian (1) 1
Swedish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1982, ISBN 9783805524483, Volume 31., xi, 224
Book
Molecular Pharmaceutics, ISSN 1543-8384, 08/2012, Volume 9, Issue 8, pp. 2358 - 2363
The aims of this work were to study pharmacokinetics of randomly selected drugs in plasma and saliva samples in healthy human volunteers, and to introduce a... 
Salivary Excretion Classification System | effective permeability | pharmacokinetics | protein binding | bioequivalence | SimCYP | MEDICINE, RESEARCH & EXPERIMENTAL | RELATIVE BIOAVAILABILITY | PERMEABILITY | CLINICAL PHARMACOKINETICS | BIOLOGICAL FLUID | DRUGS | PHARMACOLOGY & PHARMACY | Quinolines - blood | Acetates - blood | Fluorobenzenes - pharmacokinetics | Hydrochlorothiazide - pharmacokinetics | Triazoles - blood | Piroxicam - blood | Azithromycin - blood | Humans | Losartan - blood | Saliva - secretion | Male | Naphthalenes - blood | Benzhydryl Compounds - blood | Fluorobenzenes - pharmacology | Quinolines - pharmacokinetics | Sulfonamides - blood | Azithromycin - pharmacokinetics | Tolterodine Tartrate | Female | Triazoles - pharmacokinetics | Naphthalenes - pharmacokinetics | Piroxicam - analogs & derivatives | Sitagliptin Phosphate | Hydrochlorothiazide - blood | Losartan - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Metformin - blood | Cresols - blood | Phenylpropanolamine - blood | Metformin - pharmacokinetics | Rosuvastatin Calcium | Cloxacillin - pharmacokinetics | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Cinacalcet Hydrochloride | Cloxacillin - blood | Saliva - metabolism | Pyrazines - pharmacokinetics | Piroxicam - pharmacokinetics | Pyrimidines - pharmacokinetics | Cresols - pharmacokinetics | Anthraquinones - blood | Anthraquinones - pharmacokinetics | Phenylpropanolamine - pharmacokinetics | Pyrazines - blood | Acetates - pharmacokinetics | Index Medicus
Journal Article
1985, ISBN 9783805539494, Volume 34., x, 208
Book
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 04/2012, Volume 22, Issue 4, pp. 310 - 318
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
SUMMARY • Non-steroidal anti-inflammatory drugs (NSAIDs) cause renal side-effects. In the present study, we tested the hypothesis that the extent of the renal... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | GASTROINTESTINAL TOXICITY | PHYSIOLOGY | CYCLOOXYGENASE-2 | RAT | HYPERKALEMIA | PROTEIN-BINDING | MELOXICAM | INTERSPECIES DIFFERENCES | GENTAMICIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY & PHARMACY | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics | Index Medicus
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2015, Volume 63, Issue 4, pp. 805 - 812
Background & Aims Paritaprevir, ombitasvir, and dasabuvir are direct-acting antivirals for treatment of chronic hepatitis C virus (HCV) infection. The aim of... 
Gastroenterology and Hepatology | Direct-acting antiviral agents | Ombitasvir | Chronic hepatitis C | Hepatic impairment | Ritonavir | Paritaprevir | Pharmacokinetics | Dasabuvir | ABT-450/R-OMBITASVIR | TRANSPORTER EXPRESSION | RIBAVIRIN | LIVER-DISEASE | GENOTYPE 1 | THERAPY | CIRRHOSIS | HCV | GASTROENTEROLOGY & HEPATOLOGY | Antiviral Agents - pharmacokinetics | Humans | Middle Aged | Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Hepatitis C, Chronic - complications | Carbamates - pharmacokinetics | Dose-Response Relationship, Drug | Uracil - administration & dosage | Ribavirin - administration & dosage | Ribavirin - pharmacokinetics | Female | Drug Therapy, Combination | Liver Function Tests | Cytochrome P-450 CYP3A Inhibitors - administration & dosage | Ritonavir - administration & dosage | Macrocyclic Compounds - pharmacokinetics | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatic Insufficiency - blood | Hepatitis C, Chronic - blood | Sulfonamides - pharmacokinetics | Ritonavir - pharmacokinetics | Anilides - administration & dosage | Macrocyclic Compounds - administration & dosage | Hepatic Insufficiency - etiology | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Antiviral agents | Safety and security measures | Hepatitis C virus | Hepatitis C | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Background. Boceprevir represents a new treatment option for hepatitis C (HCV)—infected patients, including those with HCV/human immunodeficiency virus... 
HIV/AIDS | HIV | Protease inhibitors | Geometric mean | Memory interference | Drug interactions | Infections | Sample mean | Pharmacokinetics | Dosage | Hepacivirus | pharmacokinetics | darunavir | boceprevir | lopinavir | atazanavir | INFECTIOUS DISEASES | PLUS RIBAVIRIN | DRUG-INTERACTIONS | MICROBIOLOGY | IMMUNOLOGY | OATP1B1 | CYP3A | INTERFERON | COCKTAIL | CYTOCHROME-P450 ENZYMES | GENOTYPE 1 INFECTION | Hepacivirus - drug effects | Darunavir | Proline - analogs & derivatives | Area Under Curve | HIV-1 - drug effects | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Oligopeptides - pharmacokinetics | Pyridines - pharmacokinetics | Male | Sulfonamides - pharmacokinetics | Lopinavir - pharmacokinetics | Proline - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Ritonavir - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Boceprevir | Pharmacology, Experimental | Atazanavir | Lopinavir | Dosage and administration | Drug therapy, Combination | Hepatitis C virus | Drug therapy | Health aspects | Clinical trials | Hepatitis | Prescription drugs | Pharmacology | Human immunodeficiency virus--HIV | Index Medicus | All-terrain vehicles | Antiviral agents | Side effects | Ritonavir | Drug interaction | Proteinase inhibitors | Hepatitis C
Journal Article
American Journal of Transplantation, ISSN 1600-6135, 05/2015, Volume 15, Issue 5, pp. 1313 - 1322
The authors describe the drug–drug interaction profile of the he patitis C direct‐acting antiviral agents ABT‐450, ombitasvir, and dasabuvir with cyclosporine... 
infectious disease | clinical research/practice | pharmacology | calcineurin inhibitor: cyclosporine A (CsA) | pharmacokinetics/pharmacodynamics | immunosuppressant | infection and infectious agents | calcineurin inhibitor: tacrolimus | liver transplantation/hepatology | viral: hepatitis C | SURGERY | ABT-450/R-OMBITASVIR | LIVER-TRANSPLANTATION | EFFICACY | DRUG-INTERACTIONS | TRANSPORTERS | INFECTION | HCV | RIBAVIRIN | INHIBITOR | HEPATITIS-C | TRANSPLANTATION | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Area Under Curve | Humans | Middle Aged | Male | Anilides - pharmacokinetics | Carbamates - administration & dosage | Healthy Volunteers | Carbamates - pharmacokinetics | Young Adult | Uracil - administration & dosage | Cyclosporine - pharmacokinetics | Adult | Female | Tacrolimus - administration & dosage | Hepacivirus - drug effects | Drug Administration Schedule | Macrocyclic Compounds - pharmacokinetics | Tacrolimus - pharmacokinetics | Antiviral Agents - administration & dosage | Sulfonamides - pharmacokinetics | Anilides - administration & dosage | Adolescent | Cyclosporine - administration & dosage | Macrocyclic Compounds - administration & dosage | Uracil - pharmacokinetics | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Dosage and administration | Liver diseases | Drug therapy, Combination | Tacrolimus | Hepatitis C virus | Hepatitis C | Hepatitis | Medical research | Drug dosages | Index Medicus | practice | pharmacodynamics | hepatology | clinical research | pharmacokinetics | Original | liver transplantation
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 11/2016, Volume 56, Issue 11, pp. 1335 - 1343
Journal Article